Improving outcome in the first-line management of advanced ovarian cancer

[1]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Gore,et al.  Intraperitoneal chemotherapy in ovarian cancer remains experimental. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Reuss,et al.  Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. , 2006, Journal of the National Cancer Institute.

[4]  C. Aghajanian.  The role of bevacizumab in ovarian cancer--an evolving story. , 2006, Gynecologic oncology.

[5]  R. Burger,et al.  Bevacizumab in patients with advanced platinum-resistant ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Alberts,et al.  Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Bookman,et al.  GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Kimmig,et al.  Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationau , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[10]  S. Loibl,et al.  Paclitaxel‐carboplatin‐gemcitabine (TCG) as first‐line treatment of ovarian cancer: a prospective multicenter phase II study (AGO‐OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO‐OVAR 9, GINECO‐TCG, NSGO‐OC‐0102) comparing TCG with standard TC , 2005 .

[11]  H. Kitchener,et al.  Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Campbell,et al.  The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .

[13]  R. Ozols.  Treatment goals in ovarian cancer , 2005, International Journal of Gynecologic Cancer.

[14]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[15]  S. Pignata,et al.  Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Parazzini,et al.  Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study , 2004, International Journal of Gynecologic Cancer.

[17]  E. Eisenhauer,et al.  First‐line treatment of ovarian cancer FIGO stages IIb–IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[18]  B. Monk,et al.  Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Piccart,et al.  INTRAPERITONEAL (IP) CISPLATIN (P) VERSUS NO FURTHER TREATMENT: 8 YEAR-RESULTS OF AN EORTCGCG RANDOMIZED PHASE III STUDY IN OVARIAN CANCER (O.C.) PATIENTS (PTS) WITH A PATHOLOGICALLY COMPLETE REMISSION (PCR) AFTER P-BASED INDUCTION CHEMOTHERAPY (CT) AND CYTOREDUCTIVE SURGERY , 2003, International Journal of Gynecologic Cancer.

[20]  I. Tannock,et al.  Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial , 2002, The Lancet.

[21]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Eisenhauer,et al.  Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Pérez.  Paclitaxel in Breast Cancer. , 1998, The oncologist.

[24]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.